



Astec LifeSciences Ltd.

Date: 26th October, 2026

To,
BSE Limited
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

Ref.: BSE Scrip Code No. “533138”

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra – Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: “ASTEC”

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08023

Dear Sir / Madam,

Sub.: Press Release

The Board of Directors of Astec LifeSciences Limited (“the Company”), at its Meeting held on **Monday, 26th October, 2026**, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Half Year ended 30th September, 2026.

We enclose a copy of the Press Release and the same is being placed on the website of the Company (www.godrejastec.com).

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree
Rohan
Pradhan
Date: 2026.10.26
19:01:35 +05'30'

Tejashree Pradhan

Company Secretary & Compliance Officer
(FCS 7167)

Encl.: As above



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236



ASTEC
ASTEC LIFESCIENCES LIMITED

“Godrej One”, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

PRESS RELEASE

Mumbai, 26th October 2026: Astec LifeSciences Limited (“Astec”) has today announced its financial results for the second quarter and first half of FY27.

FINANCIAL OVERVIEW

Particulars (₹ cr)	Q2FY27	Q2FY26	% Change	H1FY27	H1FY26	% Change
Total Income	72.6	74.8	(3%)	156.9	166.4	(6%)
Earnings before Depreciation, Interest and Tax (EBITDA)	(19.2)	(5.6)	n.m.	(19.1)	(16.1)	n.m.
Profit/(Loss) before Tax	(37.4)	(24.4)	n.m.	(56.2)	(57.4)	n.m.
Profit/(Loss) after Tax	(37.4)	(24.4)	n.m.	(56.1)	(57.4)	n.m.

n.m.: not measurable

Q2 FY27 Financial Summary

- Consolidated total income of ₹72.6 crore in Q2 FY27 vs. ₹74.8 crore in Q2 FY26.
- Consolidated EBITDA of (₹19.2 crore) in Q2 FY27 vs. (₹5.6 crore) in Q2 FY26.
- Reported loss after tax of (₹37.4 crore) in Q2 FY27 vs. (₹24.4 crore) in Q2 FY26.

H1 FY27 Financial Summary

- Consolidated total income of ₹156.9 crore in H1 FY27 vs. ₹166.4 crore in H1 FY26.
- Consolidated EBITDA of (₹19.1 crore) in H1 FY27 vs. (₹16.1 crore) in H1 FY26.
- Reported loss after tax of (₹56.1 crore) in Q2 FY27 vs. (₹57.4 crore) in H1 FY26.

CHAIRPERSON'S COMMENTS

Commenting on the performance, Mr. Vishal Sharma, Chairperson, Astec LifeSciences Limited, said:

The demand across key agrochemical markets worsened due to adverse weather conditions in certain regions, elevated channel inventories, and cautious procurement by customers. We are seeing the El Niño impact and that combined with poor rainfall in many parts of India has led to a demand weakening. Export sales were further impacted by channel destocking, overall pricing pressure, and weaker demand across select export markets as the overall sentiment is one of caution.

Astec reported consolidated income of ₹72.6 crore in Q2 FY27 versus ₹74.8 crore in Q2 FY26. The Company's EBITDA was (₹19.2 crore) in the quarter as compared to an EBITDA of (₹5.6 crore) in the same period last year. Performance was impacted by lower volumes in its key enterprise products, reduced realizations and elevated input costs due to pricing pressures. In addition, ongoing geopolitical uncertainties have resulted in continued volatility in raw material prices, necessitating an inventory write down of Rs. 3 crore to net realizable value.

Revenue from Enterprise Products stood at ₹57 crore in Q2 FY27, as compared to ₹61 crore in Q2 FY26, primarily led by lower volumes in its key enterprise molecules and reduced realizations.

Revenue from CDMO Products grew by 15% y-o-y to ₹15 crore in Q2 FY27 compared to ₹13 crore in Q2 FY26.

The Company is focused on expanding its growth platform through enhanced business development efforts and new product introductions, alongside ongoing initiatives to improve capacity utilizations, optimize costs, and strengthen operational performance.

Revenue from Operations (₹ cr)	Q2FY27	Q2FY26	% Change	H1FY27	H1FY26	% Change
Category Breakdown	72.0	73.7	(2%)	155.6	164.8	(6%)
Enterprise	57.0	60.6	(6%)	108.7	97.1	12%
Contract Manufacturing & New Products	15.0	13.1	15%	46.9	67.7	(31%)
Geography Breakdown	72.0	73.7	(2%)	155.6	164.8	(6%)
Exports	28.9	41.1	(30%)	62.2	87.0	(28%)
Domestic	43.1	32.6	32%	93.4	77.8	20%

About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to several including the United States and countries across Europe, West Asia, South-East Asia and Latin America and Africa.

For more information on the Company, please log on to www.godrejastec.com

For further information, please contact:

Anurag Gupta

Head, Investor Relations

Godrej Agrovet Limited

Email: anurag.gupta3@godrejagrovvet.com

Disclaimer: "Some of the statements in this communication may be 'forward looking statements' within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations."